Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention.

In conclusion, the results of this trial showed that during 6 months of follow-up, the empagliflozin and placebo groups were not significantly different in terms of the incidence of major CV complications including coronary revascularization, hospitalization due to unstable angina, and CV death; although, we observed a positive trend.

also in 11,005 other papers